<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148109</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2004-078</org_study_id>
    <secondary_id>Legacy IRB #2005-0072</secondary_id>
    <nct_id>NCT00148109</nct_id>
  </id_info>
  <brief_title>Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas</brief_title>
  <official_title>Phase II Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ImClone LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore how this cancer is affected by a new medication,
      cetuximab. Cetuximab is directed towards a protein called EGFR (epidermal growth factor
      receptor), that is found in some types of cancer. Studies have shown that this drug can be
      beneficial in patients with colon cancer and has been approved by the US Food and Drug
      Administration (FDA) for this purpose. The researchers are conducting a study to see if it is
      beneficial in patients with sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcomas are mesenchymal malignancies that arise in the connective tissue throughout the body
      and afflict approximately 11,000 people in the United States yearly. Sarcomas are
      heterogeneous with well over 50 subtypes described. The peak incidence is subtype-specific
      with certain sarcomas seen in children and young adults while other subtypes peak in late
      middle-age, causing significant morbidity and mortality in young patients and productive
      adults.

      The precise etiology for most sarcomas remains unknown. External radiation therapy is an
      established risk factor. Other risk factors include occupational exposures to certain
      chemicals, lymphedema, and hereditary conditions such as neurofibromatosis and Li-Fraumeni
      syndrome. Many sarcomas are associated with specific somatic genetic alterations. For
      example, some specific subtypes are associated with gene translocations causing aberrant
      fusion proteins including Ewing sarcoma (EWS-FLI-1), synovial sarcoma (SSX-SYT), alveolar
      rhabdomyosarcoma (PAX3-FHKR), and myxoid liposarcomas (TLS-CHOP). These singular molecular
      alterations imply that some sarcomas are cytogenetically simple and may be more appropriate
      substrates for therapy targeted to a single molecular pathway.

      Sarcomas are commonly present as an asymptomatic mass or with local symptoms in an extremity
      or the retroperitoneum. Although tumor size, location, and histologic subtype have been
      implicated as prognostic factors in sarcomas, histologic grade remains the most important
      factor. Tumor grade is based on the degree of cellularity, differentiation, pleomorphism,
      necrosis, and the number of mitoses. Approximately 50-60% of patients with high grade soft
      tissue sarcoma will eventually have metastatic disease, as compared to 5-10% of patients with
      low grade disease.

      Sarcomas spread hematogenously with the most common site of spread being the lung, followed
      by liver, bone, and brain. About 50% of patients with sarcoma eventually expire due to
      locally advanced or metastatic disease with a median survival of 8-12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Sarcoma Who Are Tumor Progression Free and Alive at Four Months From Start of Treatment With Single-agent Cetuximab.</measure>
    <time_frame>4 months</time_frame>
    <description>Time of cetuximab administration to clinically documented progression of disease or death assessed for four months after starting cetuximab therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival.</measure>
    <time_frame>survival</time_frame>
    <description>Time of cetuximab administration to clinically documented progression of disease or death assessed for four months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>months</time_frame>
    <description>Time of cetuximab administration to clinically documented death assessed for four months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>EGFR positive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The EGFR positive group will be conducted in a 2-stage minimax trial design to determine the rate of four-month progression free survival in this patient population treated with cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGFR Negative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The EGFR negative group will help us explore the possibility of benefit of cetuximab in a patient whose tumor does not express or minimally expresses EGFR. If benefit in progression-free survival or in another surrogate such as tumor response or a molecular event is seen in this group it would provide rationale to study this group further in subsequent trials</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.</description>
    <arm_group_label>EGFR positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min</description>
    <arm_group_label>EGFR Negative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for the study, patients must fulfill all of the following criteria:

          1. Patients must have the ability to give informed consent and have signed an approved
             informed consent form.

          2. Patients must have a pathologic diagnosis of soft tissue sarcoma or bony sarcoma.

          3. Patients with tumor tissue available for assessment of EGFR status performed by
             immunohistochemistry (IHC).

          4. Patients with Zubrod performance status 0-2.

          5. Patients must be 16 years of age or older.

          6. Patients, 16 years or older, must either be not of child bearing potential or have a
             negative pregnancy test within 7 days of treatment. Patients are considered not of
             child bearing potential if they are surgically sterile (they have undergone a
             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are
             postmenopausal.

          7. If patients are childbearing or have child-fathering potential, they must use barrier
             contraception during intercourse while being treated on this study.

          8. Bone marrow function: absolute neutrophil count (ANC) 1,000/ul; platelets 75,000/l.

          9. Renal function: creatinine 2.0 x institutional upper limit of normal (ULN).

         10. Hepatic function: bilirubin 2.5 x ULN; AST 5.0 x ULN.

         11. Patients must have received at least one systemic chemotherapy treatment or else
             refuse to be treated with cytotoxic therapy.

         12. Twenty-eight days or more should have elapsed since the patient has received any prior
             systemic therapy.

         13. Patients must have documented symptomatic or radiologic progression to their preceding
             therapy.

         14. For patients treated with prior radiation, 21 days or more should have elapsed since
             the administration of the last fraction of radiation therapy and patients must have
             recovered from all associated toxicities.

         15. Patients must have measurable disease. The measurable lesion should be outside
             previously irradiated fields or have documented progression at least 6 weeks after
             completion of radiation.

        Exclusion Criteria:

        Any of the following criteria will make the patient ineligible to participate in this
        study:

          1. Acute hepatitis or known HIV.

          2. Active or uncontrolled infection.

          3. Significant history of uncontrolled cardiac disease i.e., uncontrolled hypertension,
             unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled
             congestive heart failure, and cardiomyopathy with decreased ejection fraction.

          4. Prior therapy which specifically and directly targets the EGFR pathway.

          5. Prior severe infusion reaction to a monoclonal antibody.

          6. Any concurrent chemotherapy not indicated in the study protocol or any other
             investigational agent(s).

          7. Other active systemic malignancy within the past year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rashmi Chugh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>April 12, 2011</results_first_submitted>
  <results_first_submitted_qc>August 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2011</results_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable/metastatic high grade soft tissue bony sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>36 subjects were recruited between June of 2005 and June of 2008 in the Comprehensive Cancer Center outpatient Oncology Clinics at the University of Michigan Health Systems</recruitment_details>
      <pre_assignment_details>Potential participants who appeared to meet study criteria were approached with a brief discussion of the study. If interested, a more in - depth detail discussion of the risks and benefits of potentially participating in the study took place with the subject as well as any family members that may have been present.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Epidermal Growth Factor Receptor Negative</title>
          <description>Sarcoma does not express Epidermal growth factor receptor. Patients received cetuximab 400 mg per meter squared IV followed by 250 mg per meter squared weekly</description>
        </group>
        <group group_id="P2">
          <title>Epidermal Growth Factor Receptor Positive</title>
          <description>Sarcoma expresses Epidermal growth factor receptor. Patients received cetuximab 400 mg per meter squared IV followed by 250 mg per meter squared weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Epidermal Growth Factor Receptor Negative</title>
          <description>Sarcoma does not express Epidermal growth factor receptor. Patients received cetuximab 400 mg per meter squared IV followed by 250 mg per meter squared weekly</description>
        </group>
        <group group_id="B2">
          <title>Epidermal Growth Factor Receptor Positive</title>
          <description>Sarcoma expresses Epidermal growth factor receptor. Patients received cetuximab 400 mg per meter squared IV followed by 250 mg per meter squared weekly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="2" lower_limit="23" upper_limit="77"/>
                    <measurement group_id="B2" value="54" spread="2" lower_limit="29" upper_limit="78"/>
                    <measurement group_id="B3" value="54" spread="2" lower_limit="23" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Sarcoma Who Are Tumor Progression Free and Alive at Four Months From Start of Treatment With Single-agent Cetuximab.</title>
        <description>Time of cetuximab administration to clinically documented progression of disease or death assessed for four months after starting cetuximab therapy</description>
        <time_frame>4 months</time_frame>
        <population>per protocol all patients that received drug were evaluated for the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Epidermal Growth Factor Receptor Negative</title>
            <description>Tumor did not express epidermal growth factor receptor</description>
          </group>
          <group group_id="O2">
            <title>Epidermal Growth Factor Receptor Positive</title>
            <description>Tumor did express epidermal growth factor receptor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Sarcoma Who Are Tumor Progression Free and Alive at Four Months From Start of Treatment With Single-agent Cetuximab.</title>
          <description>Time of cetuximab administration to clinically documented progression of disease or death assessed for four months after starting cetuximab therapy</description>
          <population>per protocol all patients that received drug were evaluated for the primary endpoint</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimate a 4 month progression-free survival rate for each group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival.</title>
        <description>Time of cetuximab administration to clinically documented progression of disease or death assessed for four months</description>
        <time_frame>survival</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epidermal Growth Factor Receptor Negative</title>
            <description>Tumor did not express epidermal growth factor receptor</description>
          </group>
          <group group_id="O2">
            <title>Epidermal Growth Factor Receptor Positive</title>
            <description>Tumor did express epidermal growth factor receptor</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival.</title>
          <description>Time of cetuximab administration to clinically documented progression of disease or death assessed for four months</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.8" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time of cetuximab administration to clinically documented death assessed for four months</description>
        <time_frame>months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epidermal Growth Factor Receptor Negative</title>
            <description>Tumor did not express epidermal growth factor receptor</description>
          </group>
          <group group_id="O2">
            <title>Epidermal Growth Factor Receptor Positive</title>
            <description>Tumor did express epidermal growth factor receptor</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time of cetuximab administration to clinically documented death assessed for four months</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="7.7" upper_limit="25.3"/>
                    <measurement group_id="O2" value="7.7" lower_limit="4.2" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Epidermal Growth Factor Receptor Negative</title>
          <description>Sarcoma does not express Epidermal growth factor receptor. Patients received cetuximab 400 mg per meter squared IV followed by 250 mg per meter squared weekly</description>
        </group>
        <group group_id="E2">
          <title>Epidermal Growth Factor Receptor Positive</title>
          <description>Sarcoma expresses Epidermal growth factor receptor. Patients received cetuximab 400 mg per meter squared IV followed by 250 mg per meter squared weekly</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower GI Bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Upper GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>intestinal ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death due to disease progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>spinal cord compression</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>unrelated to treatment. Related to tumor progession of underlying disease</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Acute Neurological Symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Chest Pressure and Shortness of Breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>infusion reaction</sub_title>
                <description>allergic reaction to infusion</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>diffuse erythemitus rash</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>accrual to EGFR + cohort suspended after first step for lack of efficacy of cetuximab.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Rashmi Chugh</name_or_title>
      <organization>University of Michigan Comprehensive Cancer Center</organization>
      <phone>(734) 936-5710</phone>
      <email>rashmim@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

